Health and Healthcare
Pfizer and Eli Lilly Win in Late-Stage Osteoarthitis Study
Published:
Last Updated:
Pfizer Inc. (NYSE: PFE) and Eli Lilly and Co. (NYSE: LLY) shares were largely unaffected after the firms announced results from a joint late-stage trial in patients with osteoarthritis (OA) pain. Overall the results were fairly positive, and tanezumab met all three co-primary endpoints.
The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and overall assessment of their OA, compared to those receiving placebo.
For some quick background: tanezumab is part of an investigational class of pain medications known as nerve growth factor inhibitors, and in addition to OA pain, it is being evaluated for chronic low back pain and cancer pain (due to bone metastases).
In June 2017, Pfizer and Eli Lilly announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for tanezumab for the treatment of OA pain and chronic low back pain.
Ken Verburg, tanezumab development team leader, Pfizer Global Product Development, commented:
There is a substantial need for innovative new treatment options for osteoarthritis, as many patients are unable to find relief with currently available medicines and continue to suffer. We are encouraged by these results, which speak to the potential of tanezumab as a non-opioid treatment option for pain reduction and improvement in physical function in people living with osteoarthritis pain.
Shares of Pfizer were last seen trading at $37.54, with a consensus analyst price target of $39.80 and a 52-week trading range of $32.32 to $39.43.
Eli Lilly shares were trading at $89.30. The consensus price target is $92.47, and the 52-week range is $73.69 to $89.69.
24/7 Wall St.Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying 1.5%, 2%, and even 5% cash back today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Or you can jump straight to our top pick today which pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.